Skip to main content

Table 4 Importance of each study for the comparisons in the Parkinson’s data

From: The statistical importance of a study for a network meta-analysis estimate

 

Comparisons

          

Study

Design

1:2

1:3

1:4

1:5

2:3

2:4

2:5

3:4

3:5

4:5

1

1:3

0.029

0.531

0.405

0.364

0.418

0.294

0.264

0.126

0.092

2

1:2

0.756

0.076

0.121

0.104

0.402

0.379

0.345

0.013

0.009

3

1:2:4

0.244

0.469

0.595

0.553

0.503

0.617

0.582

0.126

0.092

4

3:4

0.005

0.128

0.101

0.086

0.130

0.064

0.056

0.535

0.449

5

3:4

0.002

0.061

0.048

0.041

0.062

0.030

0.026

0.339

0.266

6

4:5

0.178

0.157

0.285

0.577

7

4:5

0.105

0.092

0.177

0.423

Direct evidence (%)

97.1

53.1

47.4

0.0

0.0

55.8

0.0

87.4

0.0

1.0

  1. Direct evidence is printed in bold. The last row shows the proportion of direct evidence for each comparison. 1 = placebo, 2 = pramipexole, 3 = ropinirole, 4 = bromocriptine, 5 = cabergoline